ERBB2 and ductal breast carcinoma in situ: Subtype analyses confirmed that the eradication rate of DCIS was significantly higher in HER2-positive disease treated by NACT than ER-positive/HER2-negative DCIS treated by NET (46% vs. 15%, p = 0.003).